AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05741112 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable device
Description: The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.
Study NCT05535413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTD1 combined with capecitabine
Description: UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle.
Study NCT05099744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electrostimulation Therapy
Description: During 20 minutes participants are connected to the handles and receive electrostimulation therapy.
Study NCT05099744 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: During 20 minutes participants receive a session of relaxation with guided imagination. These sessions will be implemented by a trained therapist who will follow a script. The relaxation sessions are based on Schultz's autogenic relaxation training, a relaxation technique based on autosuggestion.
Study NCT05099744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: During 20 minutes participants receive a session of relaxation with guided imagination. These sessions will be implemented by a trained therapist who will follow a script. The relaxation sessions are based on Schultz's autogenic relaxation training, a relaxation technique based on autosuggestion.
Study NCT05099744 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During 20 minutes participants will be connected to the handles but will not receive any frequency.
Study NCT05915780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling
Description: The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period
Study NCT05915780 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Balance Board
Description: Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
Study NCT05156775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serratus Plane Block (SPB)
Description: While the patient is in the supine position, the arm will be abducted, the ultrasound probe will be placed over the mid-clavicular region of the thoracic cage in sagittal plane. Ribs will be counted until the fifth rib will be identified in the midaxillary line. the latissimus dorsi (superficial and posterior ), teres major (superior), and serratus muscle (deep and inferior)will be identified overlying the fifth rib. As an extra reference point, thoracodorsal artery will be used, this aids in the identification of the plane superficial to the serratus muscle, 30 ml 0.25 %bupivacaine will be injected between latissimus dorsi and serratus anterior muscles at the level of the 5th rib in the mid axillary line.
Study NCT05156775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal nerve block (RIB)
Description: In the rhomboid intercostal nerve block (RIB) group, the patient will be placed in a lateral position with the affected breast at the top. The ipsilateral arm will be extended to the same level as the ipsilateral chest and breast, and the scapula will be moved outward. On the oblique sagittal plane, a high frequency (6-12MHz) linear ultrasound probe will be placed on the medial edge of the scapula. The US landmarks, trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung will be identified. Under the aseptic condition, a 22-gauge needle will be inserted in the plan to the US probe at T5 to T6 levels. Then, 0.25% bupivacaine (30 mL) will be injected into the inter-fascial plane between the rhomboid major muscle and the intercostal muscle, the diffusion of bupivacaine in the fascia between the rhomboid muscle and the intercostal muscle will be visualized. Then, the patient will be positioned in supine position.
Study NCT06318494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: jumping performance
Description: Patients suffering from chronic ankle instability symptomatic of recurrent subjective and objective instability will be considered. Patients will be compared to a control group of healthy volunteer subjects.~T0 Explanation of the study and written informed consent.~* Verification of inclusion/exclusion criteria and verification of previous or ongoing treatments.~* AOFAS Rating Scales,~* Tegner activity level~* Vertical Jump Test (CMJ) by foot pedal
Study NCT06318494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: jumping performance
Description: Patients suffering from chronic ankle instability symptomatic of recurrent subjective and objective instability will be considered. Patients will be compared to a control group of healthy volunteer subjects.~T0 Explanation of the study and written informed consent.~* Verification of inclusion/exclusion criteria and verification of previous or ongoing treatments.~* AOFAS Rating Scales,~* Tegner activity level~* Vertical Jump Test (CMJ) by foot pedal
Study NCT04864951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Colli-Pee urine collection device
Description: first-void urine is collected using Colli-Pee and subsequently analyzed using Anyplex™ II HPV HR Detection from Seegene.
Study NCT04864951 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Subjects are asked to complete a survey that includes questions about sexual orientation, hormone therapy, gender reassignment surgery, number of sexual partners, HPV vaccination, and smoking
Study NCT04386642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid 2000 mg dilute in normal saline solution 50 ml.
Study NCT04386642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline solution in a clear 50-ml syringe
Study NCT04891354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDNO
Description: PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
Study NCT04891354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride (placebo)
Description: Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
Study NCT00430092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate
Study NCT00430092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05351788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
Study NCT05346406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Peripheral Catheter
Description: Bard Powerglide 8 cm midline catheter
Study NCT05346406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripherally Inserted Central Catheter
Description: Bard 3fr, 4fr or 6fr; Cook 4fr; or Medcomp 1.9fr and 2.6fr
Study NCT05351788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-A167
Description: KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
Study NCT05313087 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: assess response to vaccine
Study NCT05981690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided, parent-led CBT for preadolescent children with OCD
Description: This treatment was adapted from an existing evidence based therapist guided parent-led CBT intervention for preadolescent children with anxiety difficulties. It consists of 6 to 8 treatment individual treatment sessions where parents learn CBT techniques to apply at home with their child
Study NCT06422013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GTB1
Description: oral administration of GTB1 powder packet once daily
Study NCT06422013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo powder packet once daily
Study NCT06330207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support tool
Description: The intervention involves two strategies. The first strategy is education where at baseline participants will complete the one-hour online Smiles for Life oral health educational module on acute dental problems, which includes NTDC management. This module can be completed in multiple sessions. Providers will be asked to share the certificate of completion that is provided to them via the website by passing a post knowledge test. The second strategy is CDST. Providers who completed NTDC module certificate will pilot test the CDST which is an algorithm that walks the ED provider thru patient's signs and symptoms and identifies guideline-recommended treatments available in the ED.
Study NCT06154356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation and motor imagery therapy for rehabilitation
Description: Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching.
Study NCT06154356 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham action observation and motor imagery therapy for rehabilitation
Description: Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions.
Study NCT05429398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib Tablet
Description: 1. Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle;~2. Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib.
Study NCT04304872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, we have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.
Study NCT04304872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-Framed Financial Incentives
Description: Participants are informed that each week $14 is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
Study NCT06259825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs)
Description: At least four portions of omega-3 PUFA enriched chicken-meat (whole chickens, breasts, thighs and drums) and at least four omega-3 PUFA enriched eggs will be consumed weekly for 4 months. The poultry meat and eggs will be enriched by feeding chickens a complete feed which includes algae, which is a rich source of omega-3 PUFAs (OmegaPro, Humanitiv, Meath, Ireland).
Study NCT06259825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control poultry foods (chicken-meat and eggs)
Description: At least four portions of standard chicken-meat (whole chickens, breasts, thighs and drums) and at least four standard eggs will be consumed weekly for 4 months.
Study NCT06273397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 MG
Description: Acetazolamide 250mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
Study NCT06273397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone 2.5 MG
Description: Metolazone 2.5mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
Study NCT06273397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.
Study NCT06273397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection
Description: Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.
Study NCT05309148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on eye tracker based device
Description: The intervention is based on the principle of visual biofeedback. The patient sees where his gaze is and can objectively assess and correct his visual error.
Study NCT05309148 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training with a neuropsychologist
Description: The intervention is based on classical neuropsychological techniques aimed at correcting oculomotor disorders and improving visual attention (blank, psychometric, etc.)
Study NCT05309148 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training on eye tracker based device and with a neuropsychologist
Description: This is combination of the first and second interventions
Study NCT06288074 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-omics tests
Description: Biological sample collection for Multi-omics tests
Study NCT05365126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complete Vocal Technique Voice Therapy
Description: A Complete Vocal Technique (CVT) Practitioner will assess the patient's voice and voice problems using the CVT framework and then apply CVT therapy, a form of voice therapy
Study NCT06300073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: U-shaped Power Toothbrush
Description: Twice daily brushing for 30 seconds with fluoride toothpaste
Study NCT06300073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Comparator: Soft Manual Toothbrush
Description: Twice daily brushing for 2 minutes with fluoride toothpaste
Study NCT04027894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin SV MMX
Description: 200 mg Rifamycin SV-MMX® (CB-01-11)
Study NCT04027894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Rifamycin SV-MMX
Description: Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
Study NCT06240104 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cardiac output index monitor
Description: During the spontaneous breathing test phase, the cardiac index (CI) is continuously monitored from 15-30 minutes prior to the start of the test. Patients who have successfully completed the spontaneous breathing test and increased their CI by more than 30% and meet ordinary weaning indications can have their tracheal intubation removed.
Study NCT06017726 — intervention group
Intervention type: OTHER
Intervention: treatment of insulin resistance with appropriate modality according to each patient
Description: insulin resistance will be treated with either diet alone or combined diet and appropriate pharmacological treatment with the net result of normalization of HOMA IR index
Study NCT06317493 — intervention group
Intervention type: OTHER
Intervention: Stimuli
Description: Auditory Stimuli: Pure tone bursts with main frequencies of 500, 1000, 2000, and 4000 Hz. Each tone will be presented at 10dB above the estimated individual threshold per frequency and compared to the responses to trials without auditory stimuli. Auditory stimulus duration: 25ms, there is 200ms baseline period before each trial, and 2000 ms interstimulus interval.~Visual stimuli: an animated movie adapted for the age and controlled for luminosity levels.~Pupil data will be collected through a Tobii PRO screen-based eye-tracker that measures eye-movements and pupil dilation using the infrared light cameras.
Study NCT05351788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
Study NCT05351788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
Study NCT05441176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Scoring of the DASH is performed according to references.
Study NCT05501340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: PD-1 inhibitor (HLX10, serplulimab) 100mg intraperitoneal infusion every two weeks after radiotherapy PD-1 inhibitor (HLX10, serplulimab) 3mg/kg intravenous infusion within one week after radiotherapy every two weeks
Study NCT05501340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim
Description: 200ug qd subcutaneous injection for 7 days
Study NCT05501340 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy/Sterotactic body radiotherapy
Description: 8Gy\*3f
Study NCT04967014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP2101
Description: Test drug
Study NCT04967014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2101
Description: Reference drug
Study NCT06419257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRDS
Description: VRDS is an augmented virtual reality driving simulator.
Study NCT05719675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The general outline of the intervention is divided into three phases:~1. Dispositional alteration, where the aim will be to obtain precise information on the barriers that patients encounter in carrying out their treatment and thus focus the issues to achieve an awareness of the disease by altering some of the factors that give rise to the realization of behaviors that interfere with treatment adherence.~2. Alteration of one's own behavior, focused on the development of healthy habits that are consistent with the indications of the health team for the proper management of the disease.~3. Alteration of the behavior of others, focused on the development of skills in the participants so that they are able to modify the behavior of other people close to them through health promotion strategies.
Study NCT06681051 — intervention group
Intervention type: DEVICE
Intervention: OSTENIL® TENDON
Description: OSTENIL® TENDON is a CE-certified viscoelastic solution intended for peritendinous or intrasheath injection, containing 2 % sodium hyaluronate from fermentation.